Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and durability of single- and
repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular
age-related macular degeneration (nAMD).